ReviewAnticancer therapy with novel tubulin-interacting drugs
References (112)
Factors determining cellular mechanisms of resistance to antimitotic drugs
Drug Resist Updates
(2001)- et al.
Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization
J Biol Chem
(1997) - et al.
A β-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance
J Biol Chem
(1999) - et al.
Vinflunine, the latest vinca alkaloid in clinical development. A review of its preclinical anticancer properties
Crit Rev Oncol Hematol
(2001) - et al.
An antimicrotubule agent, TZT-1027, does not induce neuropathologic alterations which are detected after administration of vincristine or paclitaxel in animal models
Toxicol Lett
(2001) - et al.
High resolution model of the microtubule
Cell
(1999) - et al.
Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R))
J Biol Chem
(1997) - et al.
Synthesis and biological properties of C12,13-cyclopropyl-epothilone A and related epothilones
Chem Biol
(1998) - et al.
(+)-Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest
Chem Biol
(1996) - et al.
Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial
Ann Oncol
(2000)
Past and future of the mitotic spindle as an oncology target
Curr Opin Pharmacol
Tumor targeting by conjugation of DHA to paclitaxel
J Control Rel
Dissecting cellular processes using small molecules: identification of colchicine-like, taxol-like and other small molecules that perturb mitosis
Chem Biol
A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors
Ann Oncol
Biochemistry of multidrug resistance mediated by the multidrug transporter
Annu Rev Biochem
The role of Multidrug Resistance-associated Protein (MRP) gene expression in drug resistance
Anti-Cancer Drugs
A family of drug transporters: the multidrug resistance-associated proteins
J Natl Cancer Inst
Atypical multidrug resistance: Breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines
J Natl Cancer Inst
Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific β-tubulin isotypes
J Clin Invest
The role of β-tubulin isotypes in resistance to antimitotic drugs
Biochim Biophys Acta
Multiple microtubule alterations are associated with vinca alkaloid resistance in human leukaemia cells
Cancer Res
Mutations in β-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines
Mol Cancer Therapeut
Taxol stabilizes microtubules in mouse fibroblast cells
Proc Natl Acad Sci USA
Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations
Proc Natl Acad Sci USA
Substoichiometric binding of taxol suppresses microtubule dynamics
Biochemistry
Novel actions of the antitumor drugs vinflunine and vinorelbine on microtubules
Cancer Res
Modifications in the “upper” velbenamine part of the vinca alkaloids have major implications for tubulin interacting activities
Curr Pharm Des
Vinflunine, a second generation novel vinca alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers
Curr Pharm Des
Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic vinca alkaloids vinorelbine and its newer derivative vinflunine
Mol Pharmacol
How do the newer vinca alkaloids vinflunine and vinorelbine block mitosis
Proc Am Assoc Cancer Res
Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model
Br J Cancer
Significant antiangiogenic activity and marked inhibition of growth of an orthotopic colon cancer model and colon cancer liver metastases by vinflunine, the most recent vinca alkaloid in clinical development
Proc Am Assoc Cancer Res
Markedly diminished drug-resistance inducing properties of vinflunine (20′,20′- difluoro-3′,4′- dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumour cells in vivo and in vitro, with clinical implications
Cancer Chemother Pharmacol
Antiproliferative mechanisms of action of cryptophycin-52:Kinetic stabilization of microtubule dynamics by high-affinity binding to microtubule ends
Proc Natl Acad Sci USA
Cryptophycin-induced hyperphosphorylation of Bcl-2, cell cycle arrest and growth inhibition in human H460 NSCLC cells
Cancer Chemother Pharmacol
Cryptophycin 52 and cryptophycin 55 in sequential and simultaneous combination treatment regimens in human tumour xenografts
In Vivo
Antitumour activity of cryptophycins: effect of infusion time and combination studies
Cancer Chemother Pharmacol
Cryptophycins: A novel class of potent antitumor depsipeptides
Curr Pharm Des
Interaction of dolastatin 10 with tubulin: induction of aggregation and binding and dissociation reactions
Mol Pharmacol
Phase I trial of dolastatin-10 (NSC 376128) in patients with advanced solid tumors
Clin Cancer Res
Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma
Clin Cancer Res
Dolastatin-10 in metastatic melanoma: a phase II and pharmokinetic trial of the California Cancer Consortium
Invest New Drugs
TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death
Jpn J Cancer Res
Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin
Jpn J Cancer Res
D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity
Cancer Res
A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors
Cancer Res
New antimitotic agents with activity in multi-drug resistant cell lines and in vivo efficacy in murine tumor models
J Med Chem
Plant antitumor agents VI. The isolation and structure of taxol, a novel antileukemic and antitumour agent fromtaxus brevifolia
J Am Chem Soc
Mechanism of action of taxol
Trends Pharmacol Sci
Cited by (129)
Structure-based approaches for the design of 6-aryl-1-(3,4,5-trimethoxyphenyl)-1H-benzo[d][1,2,3]triazoles as tubulin polymerization inhibitors
2024, European Journal of Medicinal ChemistryNovel combretastatin A-4 derivative containing aminophosphonates as dual inhibitors of tubulin and matrix metalloproteinases for lung cancer treatment
2022, European Journal of Medicinal ChemistryCitation Excerpt :Up still now, some of FDA approved microtubule-targeting agents are natural products or their derivatives, such as paclitaxel, vincristine and docetaxel, which are widely used and highly effective in the treatment of many solid tumors. However, the clinical utilization of these microtubule-targeting agents is primarily impeded by several defects: (i) the development of drug resistance and adverse reactions, (ii) poor solubility and low membrane permeability, (iii) complex synthesis, respectively [10–13]. Thus, these have encouraged pharmaceutical chemists to discovery novel microtubule-targeting agents for cancer therapy (see Scheme 1).
Inhibition of microtubule assembly and cytotoxic effect of graphene oxide on human colorectal carcinoma cell HCT116
2021, Archives of Biochemistry and BiophysicsQuantitative analysis of the cyclic peptide GG-8-6 in rat plasma using LC-MS/MS and its application to a pharmacokinetic study
2018, Journal of Pharmaceutical and Biomedical AnalysisInteractome Analysis of Microtubule-targeting Agents Reveals Cytotoxicity Bases in Normal Cells
2017, Genomics, Proteomics and BioinformaticsCitation Excerpt :In addition, this network plays a regulatory role in cell migration and adhesion as well [6,7]. Microtubule-targeting agents (MTAs) can affect microtubule stability, leading to disruption of the mitotic spindle and cell death [8], and are therefore one of the most effective classes of drugs used in chemotherapy against cancer. According to their binding property with tubulin, MTAs are classified as stabilizing agents (known as vinca alkaloids) [9,10], which bind the tubulin polymer, and destabilizers (known as taxanes) [11–13], which bind tubulin dimers.